Table 3.
Details of approved vaccines for the prevention of COVID-19
| Vaccines | Brand | Details | Remarks | References |
|---|---|---|---|---|
| RNA/DNA Vaccines | Comirnaty |
Pfizer- BioNTech Developed by German company BioNTech and the American company Pfizer |
•FDA Approved mRNA vaccine (August 23, 2021) •Intramuscular injection •87.9% effectiveness against symptomatic disease caused by the delta (B.1.617.2) variant •87.0–93.4% against beta variant •95.0% effectiveness against symptomatic disease caused by the alpha (B.1.1.7) variant •35% against omicron variant |
[208, 209] |
| Spikevax | Developed by American company Moderna, US National Institute of allergy and infectious diseases, US biomedical advanced research, development authority and coalition for epidemic preparedness innovations |
•Intramuscular injection •FDA Approved mRNA vaccine (January 31, 2022) •95% efficacy in preventing COVID-19 infection |
[210] | |
| ZyCoV-D | It is a plasmid-based vaccine, developed by the Indian pharmaceutical company Cadila healthcare, the biotechnology industry research assistance council |
•Efficacy to be 67.6% against symptomatic COVID-19 •DGCI approved •DNA plasmid vector vaccine •Intradermal injection |
[211] | |
| Adenovirus vector vaccines |
Covishield/ Vaxzevria |
Oxford Astra Zeneca, developed by the British university of oxford, British Swedish company AstraZeneca, coalition for epidemic preparedness innovations |
•Intramuscular injection •66.1–70.4% against beta variant •59.8% against the delta variant •62.1–76.0% effective against the alpha variant |
[209, 210] |
| Jcovden, Johnson & Johnson | It is a vector vaccine, produced by Janssen pharma, beth Israel deaconess medical center |
•Viral vector vaccine •FDA Approved vaccine •66.1% effective against the alpha variant •85% efficacy in preventing severe COVID-19 •100% efficacy in preventing hospitalization or death caused by the disease |
[209, 210] | |
| Sputnik V | It is a vector-based vaccine, produced by the Russian Gamaleya research institute of epidemiology and microbiology |
•91.6% effective against the alpha variant •Combination vector vaccine •Overall efficacy of the vaccine above 97.8% |
[209, 212] | |
| Sputnik light | It has an Ad26 vector, developed the by Russian Gamaleya research institute of epidemiology and microbiology |
•A vaccine based on recombinant adenovirus type 26 (rAd26) vector •70.2% efficacy in preventing severe COVID-19 |
[213] | |
| Convidecia | Developed by the Chinese company CanSino Biologics and the Beijing Institute of Biotechnology of the academy of military medical sciences |
•Phase III trials completed •Single dose viral vaccine •65.9% efficacy in preventing moderate symptoms of COVID 19 |
[214] | |
| Inactivated virus vaccines | Covaxin | It is developed by the Indian company Bharat Biotech in collaboration with the Indian council of medical research national institute of virology |
•65% effective against asymptomatic cases •8.1% effective against symptomatic disease •65.2% effective against delta variant •ICMR approved |
[215] |
| Sinopharm BIBP | It is produced by the China national pharmaceutical group, Beijing institute of biological products |
•Phase III trials completed •78.2% effective against symptomatic cases •74.0% effective against asymptomatic cases •78.1% effective against the alpha variant |
[216] | |
| CoronaVac | Produced by Chinese company Sinovac Biotech |
•66.0% effective against symptomatic COVID-19 •89% against hospitalization •WHO approved |
[217] | |
| VLA2001 | It is an inactivated vaccine developed by French biotechnology company Valneva SE and Dynavax technologies |
•Whole inactivated viral vaccine •Phase III trial completed with approx 4000 persons •EMA approved |
[218] | |
| Sinopharm WIBP | Developed by China’s national pharma group, the Wuhan Institute of biological products |
•72.9% effective against symptomatic cases •Phase III trials completed |
[219] | |
| CoviVac | Produced by the Chumakov center at the Russian Academy of Sciences |
•Phase I/II trial started •Required two doses •Transported and stored at normal refrigerator temperature |
[220] | |
| QazVac | It is also called as QazCovid-in vaccine, developed by a research institute for biological safety |
•Phase III trials continue •Stored at standard refrigeration temperatures •Safe and no adverse effect |
[221] | |
| Minhai PPV23 | It is an inactivated vaccine, by Minhai biotechnology Co, Shenzhen Kangtai biological products Co. Limited China |
•Injected intramuscular •Approved by national regulatory authorities •Phase III trials started |
[222] | |
| COVIran Barekat | By Shifa Pharmed Industrial Co |
•Injected intramuscular •Approved by national regulatory authorities •Phase III trials showed safe and effective results •Trials going on children |
[223] | |
|
Chinese Academy of medical sciences COVID vaccine |
It is developed by the Chinese academy of medical sciences |
•Injected intramuscular •Approved by China authorities |
[224] | |
| FAKHRAVAC | It is an inactivated vaccine, developed in Iran by the defensive innovation and research organization |
•Injected intramuscular •Phase III trials continue •Approved by Iran authorities |
[225] | |
| Turkovac | Developed by the health institute of turkey, Erciyes University |
•Phase III trials completed •Approved |
[226] | |
| Subunit vaccines | Novavax, Covovax | It is a subunit vaccine, developed by Novavax and coalition for epidemic preparedness innovations, undertrials in India |
•89.3% (phase III US) effective against the alpha variant •93.6% (phase III trial US/Mexico) effective against the beta variant |
[227] |
| Abdala | Developed by the center for genetic engineering and biotechnology in Cuba |
•Phase III trials completed •Injected intramuscular •Approved •92.2% efficacy rate •Phase I/II trials for children continue |
[228] | |
| MVC-COV1901 | It is a protein vaccine that is actually made in Taiwan by Dynavax technologies and Medigen vaccine biologics |
•Recombinant S-2P spike protein •Injected intramuscular •Immune-bridging trial continues |
[229] | |
| EpiVacCorona | The Russian state research institute for virology and biotechnology, Vector, invented the peptide vaccine |
•Injected intramuscular •Phase III trials completed •Ineffective against delta variant |
[230] | |
| Zifivax | Anhui Zhifei Longcom Biopharmaceutical developed the adjuvanted protein vaccine |
•Uzbekistan approved (1 March 2021) •Efficacy of 82.0% against the disease of any severity (August 2021) •93.0% against the alpha variant •78.1% against the delta variant |
[231] | |
| Soberana | It is a conjugated protein vaccine, by Finlay Institute in Cuba |
•91.2% effective after two doses •Approved for the children aged 3–18 years old |
[228] | |
| Corbevax | Developed by Texas children’s hospital in Texas |
•Phase III trials completed •Approved |
[232] | |
| COVAX-19 | It is also called as SpikoGen, developed by Vaxine and CinnaGen |
•Recombinant protein subunit vaccine •Approved by Iran •Clinal trials completed |
[233, 234] | |
| Razi Cov Pars | Developed by Razi Vaccine and Serum research institute |
•Recombinant protein-based vaccine •Approved •Three doses, two intramuscular and one intranasal spray |
[235] | |
| Sinopharm CNBG COVID 19 | It was actually created by the Chinese national Biotec Group |
•It is a recombinant vaccine •Intramuscular injected |
[236] | |
| Soberana plus | It is a conjugate vaccine produced by the Finlay institute | •Efficacy 91.4% against symptomatic cases | [237] | |
| Noora | It is a protein subunit vaccine that was developed by Baqiyatallah University of Medical Science |
•Recombinant vaccine •Intramuscular injected |
[238] | |
| SKYCovione | SK Bioscience developed the protein-based vaccine |
•Recombinant vaccine •Approved |
[239] |
*The information provided in the table is according to the latest data and survey (September 2022)